viernes, 6 de septiembre de 2019

What separates good drug companies from mediocre ones?

The Readout
Damian Garde

What separates good drug companies from mediocre ones?


Have biohackers sold out? And who's going to run the FDA?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT's Matthew Herper joins us to discuss his recent look at the past 10 years of science at Pfizer and what it says about how the world's biggest makers of medicine are thinking about invention. Then, we talk about the weekend's big biohacker conference, where the fringes of science embraced a bit of the mainstream, and hear an interview with a magician cyborg who has nearly 30 magnets and microchips implanted in her body.

You can listen to the episode here. To listen to future episodes, be sure to sign up on iTunes, Stitcher, Spotify, or wherever you get your podcasts.

No hay comentarios: